Cannabinoid receptor activation impairs fear extinction in adolescent rats but improves it in adults
A cannabinoid receptor agonist that helped adult rats overcome learned fear had the opposite effect in adolescent rats, coinciding with lower CB1 receptor levels in younger brains.
Quick Facts
What This Study Found
WIN55212-2, a CB1/CB2 receptor agonist, improved fear extinction in adult rats but impaired extinction acquisition in both adolescent and juvenile rats. CB1 receptor protein expression decreased linearly from juvenile to adolescent to adult stages in the prefrontal cortex and amygdala.
Key Numbers
CB1 receptor protein showed a linear decrease across age in both medial prefrontal cortex and amygdala. Impaired extinction in adolescents was consistent across multiple drug doses.
How They Did This
Rats at juvenile, adolescent, and adult developmental stages received WIN55212-2 or vehicle before extinction training following fear conditioning. CB1 receptor protein was quantified via Western blot in the medial prefrontal cortex and amygdala.
Why This Research Matters
The developing brain may respond to cannabinoid receptor activation differently than the adult brain, particularly for processes tied to emotional regulation and fear learning.
The Bigger Picture
These findings add to evidence that the endocannabinoid system undergoes significant maturation during adolescence, which could influence how cannabis exposure affects developing brains.
What This Study Doesn't Tell Us
Animal model; WIN55212-2 is a synthetic agonist that activates both CB1 and CB2 receptors, so effects may not directly translate to cannabis exposure in humans.
Questions This Raises
- ?Would similar age-dependent effects appear with THC or CBD rather than a synthetic agonist?
- ?Could these developmental differences explain varied therapeutic responses across age groups?
Trust & Context
- Key Stat:
- CB1 receptor protein decreased linearly from juvenile to adolescent to adult in prefrontal cortex and amygdala
- Evidence Grade:
- Single animal study using a synthetic agonist rather than plant-derived cannabinoids.
- Study Age:
- Published in 2020.
- Original Title:
- Developmental differences in the effects of CB1/2R agonist WIN55212-2 on extinction of learned fear.
- Published In:
- Progress in neuro-psychopharmacology & biological psychiatry, 99, 109834 (2020)
- Authors:
- Bisby, Madelyne A, Richardson, Rick, Baker, Kathryn D
- Database ID:
- RTHC-02427
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why did the same drug have opposite effects in young vs. adult rats?
The researchers found that CB1 receptor levels were significantly higher in younger brains, suggesting the endocannabinoid system is still maturing during adolescence. This developmental difference appears to change how the brain responds to cannabinoid receptor activation.
Does this mean cannabis-based therapies for anxiety would not work in teenagers?
This study used a synthetic agonist in rats, not cannabis in humans. The findings suggest age-dependent responses are possible, but clinical implications for human adolescents remain unknown.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-02427APA
Bisby, Madelyne A; Richardson, Rick; Baker, Kathryn D. (2020). Developmental differences in the effects of CB1/2R agonist WIN55212-2 on extinction of learned fear.. Progress in neuro-psychopharmacology & biological psychiatry, 99, 109834. https://doi.org/10.1016/j.pnpbp.2019.109834
MLA
Bisby, Madelyne A, et al. "Developmental differences in the effects of CB1/2R agonist WIN55212-2 on extinction of learned fear.." Progress in neuro-psychopharmacology & biological psychiatry, 2020. https://doi.org/10.1016/j.pnpbp.2019.109834
RethinkTHC
RethinkTHC Research Database. "Developmental differences in the effects of CB1/2R agonist W..." RTHC-02427. Retrieved from https://rethinkthc.com/research/bisby-2020-developmental-differences-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.